Lakefront Biotherapeutics NV current report, Q2 FY2018

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of June 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated June 26, 2018 (Exhibit 99.1), into the company's active Registration Statements on Forms F-3 and S-8.

Financial Metrics

The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing is a procedural submission to distribute a press release rather than a financial report.

Material Changes

The filing does not detail material changes in financial position or operations. It solely references the issuance of a press release on June 26, 2018, which is attached as Exhibit 99.1. The text notes that specific quotes from Dr. Walid Abi-Saab and Philippe Moingeon within that exhibit are not incorporated by reference into the registration statements.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. These details would be contained within the attached press release (Exhibit 99.1), the content of which is not included in the provided input text.

Key Facts for Investor Verification

  • Verify the actual content of the June 26, 2018 press release (Exhibit 99.1) to understand the material event triggering this filing.
  • Confirm the registrant name is Galapagos NV, as the metadata reference to "Lakefront Biotherapeutics NV" appears to be an error.
  • Note that specific quotes from Dr. Walid Abi-Saab and Philippe Moingeon in the press release are explicitly excluded from incorporation by reference into the company's registration statements.
  • Check the referenced Registration Statements (Forms F-3 and S-8) for the full context of the incorporated information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.